Charlie is a senior associate in our Cambridge office specialising in the commercialisation of intellectual property in the life sciences and technology sectors.
Leading associate
Intellectual Property
Corporate and commercial - Cambridge
by Colin McCall and Charlie Adams
Advising Nuclera on its US$75 million series C financing
by multiple authors
Licensing the Cabilly antibody manufacturing patents: are royalties payable on post-expiry sales?
by Charlie Adams and Adrian Toutoungi
by multiple authors
by Jason Rawkins and Simon Jupp
by multiple authors
by multiple authors